FPMODS2: Predictive Pre and Peroperative Factors for MODS-2 in Pediatric Cardiac Surgery

Sponsor
Brugmann University Hospital (Other)
Overall Status
Completed
CT.gov ID
NCT05284500
Collaborator
(none)
152
1
3.7
41.3

Study Details

Study Description

Brief Summary

Pediatric cardiac surgery has a relatively high morbi-mortality. Despite great advances in surgical techniques, today the mortality rate is about 3% and morbidity is about 30-40%. Outcome has been related to demographic factors, like age; peroperative factors, like duration of cardiopulmonary bypass as well as postoperative factors like positive fluid balance. Willems et al defined a new score (MODS2), an outcome score combining either patient's death or a high postoperative morbidity. This morbidity is defined as minimum of 2 organ failures: either respiratory insufficiency, prolonged use of inotropic agents or renal insufficiency. The aim of this study is to identify pre and peroperative factors which are predictors of MODS2. Patients operated between 2008 and 2018 for pediatric cardiac surgery with cardiopulmonary bypass will be included. Variables extracted from our database will be: sex, ASA score, cyanotic cardiac pathology, redo surgery, RACH1 score, use of antifibrinolytic agents, aortic cross-clamping, deep hypothermic circulatory arrest, selective cerebral perfusion, red cell transfusion in the operating room, administration of fresh frozen plasma in the operating room, age, preoperative weight, weight difference between preop weight and weight at postop day 2, emergency surgery, duration of aortic cross clamping, duration of selective cerebral perfusion, duration of cardiopulmonary bypass, duration off deep hypothermic circulatory arrest, duration of surgery, minimal core temperature, cardiopulmonary priming volume, calculated hemodilution, use of red blood cells in the cardiopulmonary bypass priming, preoperative hemoglobin, preoperative hematocrit, preoperative platelet count, preop international normalized ratio, preop fibrinogen, preop creatinin, toal fluid balance, blood loss during surgery. A statistical analysis (see detailed description) will be used to establish a prediction model for MODS2. The variables describing best the MODS2 outcome will be retained.

Condition or Disease Intervention/Treatment Phase
  • Procedure: Pediatric cardiac surgery with cardiopulmonary bypass

Detailed Description

Detailed statistical analysis:

5 multiple imputations via the mice R package will be performed, which is the most appropriate method for a risk model. We then take the mean of the imputed datasets in order to start the data mining models on one single dataset. All of the variables will be entered in the model. Before to run the data mining models, we will perform three transformations on the continuous variables: 1) standardization; 2) best normalisation via the bestNormalize R package and 3) taking the variable from its power 2 to its power 10. The dataset will be split into a training set (75% of the cases) and test set (25% of the cases). For all tested data mining models, we will use a 10-fold cross-validation method on the training set before applying the retained model on the test set. The following data mining models will be tested:

  1. a regression tree, 2) a logistic regression (GLM), 3) a Neural Network (NN); 4) a Support Vector Machine (SVM); 5) a Random Forest (RF); 6) a Multivariate Adaptive Regression Spline model (MARS) and 7) a Non-Linear Support Vector Machine (SVM NL). The models will be drawn with the caret R package. The confusion matrix, reporting the sensibilities, specificities, accuracies will be drawn on the test set based on the models developed on the training set, and the calibration plot will be drawn for three model competitors. The R software (R Core Team, 2019), version 3.6.1. will be used to produce the results.

Study Design

Study Type:
Observational
Actual Enrollment :
152 participants
Observational Model:
Cohort
Time Perspective:
Retrospective
Official Title:
Predictive Pre and Peroperative Factors for Multiple Organ Dysfunction Score 2 (MODS-2) in Pediatric Cardiac Surgery
Actual Study Start Date :
Mar 18, 2022
Actual Primary Completion Date :
Jun 30, 2022
Actual Study Completion Date :
Jul 8, 2022

Arms and Interventions

Arm Intervention/Treatment
Pediatric cardiac surgery patients

Patients undergoing pediatric cardiac surgery with cardiopulmonary bypass between 2008 and 2018 at our institution.

Procedure: Pediatric cardiac surgery with cardiopulmonary bypass
All patients undergoing pediatric cardiac surgery with cardiopulmonary bypass will be extracted from our database

Outcome Measures

Primary Outcome Measures

  1. MODS2 [28 days]

    Occurence of MODS2 (as percentage) will be extracted. A predictive model will be established from the observed preoperative and peroperative variables. A statistical analysis (see detailed description) will be used to establish a prediction model for MODS2. The variables describing best the MODS2 outcome will be retained.

Eligibility Criteria

Criteria

Ages Eligible for Study:
N/A to 16 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • patients undergoing pediatric cardiac surgery with cardiopulmonary bypass between 2008 and 2018 at our institution

  • accepting blood transfusions

  • ASA score 1-4

Exclusion Criteria:
  • Jehova's witness

  • ASA 5 status

Contacts and Locations

Locations

Site City State Country Postal Code
1 Hôpital Universitaire des Enfants Reine Fabiola Brussels Belgium 1020

Sponsors and Collaborators

  • Brugmann University Hospital

Investigators

  • Study Director: Denis Schmartz, MD, CHU Brugmann

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Denis SCHMARTZ, Head, Dept of Anesthesiology, Brugmlann University hospital & HUDERF, Brugmann University Hospital
ClinicalTrials.gov Identifier:
NCT05284500
Other Study ID Numbers:
  • FPMODS2
First Posted:
Mar 17, 2022
Last Update Posted:
Jul 20, 2022
Last Verified:
Jul 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jul 20, 2022